The Fellow on CallThe Fellow on Call | September 22, 2023
What's the best approach for treating metastatic non-small cell lung cancers that possess certain mutations?
Listen Now
Rebecca AraujoNon-Small Cell Lung Cancer | September 21, 2023
Early treatment with the anaplastic lymphoma kinase (ALK)-inhibitor lorlatinib reduced cancer progression and death in ...
Kerri FitzgeraldNon-Small Cell Lung Cancer | September 19, 2023
The U.S. Food and Drug Administration approved lorlatinib for patients with ALK-positive metastatic non-small cell ...
Latest News

February 27, 2024